305 related articles for article (PubMed ID: 36814910)
21. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
22. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
23. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
25. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L
Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
27. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma.
Ma J; Kuang L; Zhao R
Aging (Albany NY); 2022 Dec; 14(23):9699-9714. PubMed ID: 36516498
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma.
Hu Y; Liu J; Yu J; Yang F; Zhang M; Liu Y; Ma S; Zhou X; Wang J; Han Y
Cancer Cell Int; 2022 Feb; 22(1):97. PubMed ID: 35193632
[TBL] [Abstract][Full Text] [Related]
29. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
31. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
32. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
33. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
34. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.
Liu T; Wu H; Qi J; Qin C; Zhu Q
Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653
[TBL] [Abstract][Full Text] [Related]
35. Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma.
Guo Y; Yang J; Gao H; Tian X; Zhang X; Kan Q
Front Immunol; 2022; 13():927635. PubMed ID: 35874741
[TBL] [Abstract][Full Text] [Related]
36. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.
Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W
Front Immunol; 2023; 14():1204338. PubMed ID: 37680641
[TBL] [Abstract][Full Text] [Related]
37. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
39. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]